Literature DB >> 11522621

Frequent alterations of the p14(ARF) and p16(INK4a) genes in primary central nervous system lymphomas.

M Nakamura1, T Sakaki, H Hashimoto, H Nakase, E Ishida, K Shimada, N Konishi.   

Abstract

To elucidate the role of p53/p16(INK4a)/RB1 pathways in the tumorigenesis of primary central nervous system lymphomas (PCNSLs), we have analyzed p14(ARF), p16(INK4a), RB1, p21(Waf1), and p27(Kip1) status in a series of their 18 sporadic cases of diffuse large B-cell lymphoma, using methylation-specific PCR, differential PCR, and immunohistochemistry. Homozygous deletion or methylation of p14(ARF) was detected in 10 (56%) PCNSLs, and they were almost entirely deletions (except 1 case). A total of 11 (61%) PCNSLs demonstrated homozygous deletion (6 cases) or methylation (5 cases) of p16(INK4a). Six tumors showed both p14(ARF) and p16(INK4a) homozygous deletions. Hypermethylation of the RB1 and the p27(Kip1) promoter region was detected in 2 (11%) cases, whereas p21(Waf1) methylation was not detected in any. Immunohistochemistry revealed loss of p14(ARF) and p16(INK4a) expression in 10 (56%) samples, correlating with the gene status. Four cases showed independent negative immunoreactivity for pRB and p27(Kip1), and nearly one-half of cases (8 of 18; 44%) were characterized by lack of p21(Waf1) expression. These results indicate that inactivation of p14(ARF) and p16(INK4a) by either homozygous deletion or promoter hypermethylation represents an important molecular pathogenesis in PCNSLs. Hypermethylation of RB1, p21(Waf1), and p27(Kip1) appears to be of minor significance, these genes being independently methylated in PCNSLs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11522621

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Promoter hypermethylation of p73 and p53 genes in cervical cancer patients among north Indian population.

Authors:  Abhimanyu Kumar Jha; Mohsen Nikbakht; Veena Jain; Alka Sehgal; Neena Capalash; Jagdeep Kaur
Journal:  Mol Biol Rep       Date:  2012-06-24       Impact factor: 2.316

Review 2.  Epigenetic inactivation of tumor suppressor genes in hematologic malignancies.

Authors:  Tomohiro Kinoshita
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

3.  Effect of exogenous p16ink4a and hRb1 genes on cell cycle regulation of osteosarcoma cell.

Authors:  Xiang Liao; Shuhua Yang; Zengwu Shao; Jin Li; Yong Liu; Xiaoqian Xiong; Xin Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

Review 4.  The Challenge of Primary Central Nervous System Lymphoma.

Authors:  Julia Carnevale; James L Rubenstein
Journal:  Hematol Oncol Clin North Am       Date:  2016-12       Impact factor: 3.722

5.  Methylation of INK4 and CIP/KIP families of cyclin-dependent kinase inhibitor in chronic lymphocytic leukaemia in Chinese patients.

Authors:  C S Chim; T K Fung; K F Wong; J S Lau; M Law; R Liang
Journal:  J Clin Pathol       Date:  2006-03-24       Impact factor: 3.411

6.  Expression and hypermethylation of p27 kip1 in hepatocarcinogenesis.

Authors:  Pu-Ping Lei; Zong-Ji Zhang; Li-Juan Shen; Jin-Yun Li; Qiong Zou; Hua-Xian Zhang
Journal:  World J Gastroenterol       Date:  2005-08-07       Impact factor: 5.742

7.  Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas.

Authors:  Noboru Konishi; Mitsutoshi Nakamura; Munehiro Kishi; Masayoshi Nishimine; Eiwa Ishida; Keiji Shimada
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

Review 8.  Insights into the biology of primary central nervous system lymphoma.

Authors:  Maciej M Mrugala; James L Rubenstein; Maurilio Ponzoni; Tracy T Batchelor
Journal:  Curr Oncol Rep       Date:  2009-01       Impact factor: 5.075

9.  A quantitative high-throughput screen identifies potential epigenetic modulators of gene expression.

Authors:  Ronald L Johnson; Wenwei Huang; Ajit Jadhav; Christopher P Austin; James Inglese; Elisabeth D Martinez
Journal:  Anal Biochem       Date:  2007-12-25       Impact factor: 3.365

Review 10.  Therapeutic targets in the ARF tumor suppressor pathway.

Authors:  Anthony J Saporita; Leonard B Maggi; Anthony J Apicelli; Jason D Weber
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.